reports
Coeptis Therapeutics Secures Worldwide Development and Commercializati...
Coeptis Therapeutics Secures Worldwide Development and Commercialization Rights to Next-Generation GEAR™ Cell Therapy Platform Strengthening its High-Impact Precision Immuno-Oncology Pipeline • COEP forms GEAR Therapeutics, as a majority-owned subsidiary, to advance GEAR-modified natural killer (NK) cells into first-in-human studies for broad range of cancers and other therapeutic modalities. WEXFORD, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- COEPTIS, Inc. (Nasdaq: COEP) ("the Company" or "Coeptis"), a pioneering technology firm at the forefront of innovative biotechnology solutions toda...
COEPTIS’ NexGenAI Affiliates Partners with NUBURU Network to Drive Inn...
COEPTIS’ NexGenAI Affiliates Partners with NUBURU Network to Drive Innovation in AI and Robotics as Part of its Transformation Plan Leveraging Advanced AI and Robotics to Revolutionize Marketing Strategies in Defense and Security Sectors WEXFORD, Pa., March 07, 2025 (GLOBE NEWSWIRE) -- COEPTIS, Inc. (Nasdaq: COEP) ("the Company" or "COEPTIS"), a pioneering technology firm at the forefront of innovative biotechnology solutions today announced its strategic partnership with COEPTIS’ NexGenAI Affiliates Network “NexGen” and NUBURU, Inc. “NUBURU” (NYSE: BURU), a leading innovator in high-po...
COEPTIS’ NexGenAI Partners with Arketyp Valu to Revolutionize Digital ...
COEPTIS’ NexGenAI Partners with Arketyp Valu to Revolutionize Digital Engagement on the Verus Network The Strategic Collaboration Integrates Cutting-Edge Marketing Tools into the ValuSocial Platform, Leveraging the Robust Capabilities of Verus Coin and Blockchain Technology WEXFORD, Pa., Feb. 20, 2025 (GLOBE NEWSWIRE) -- COEPTIS, Inc. (Nasdaq: COEP) ("the Company" or "Coeptis"), a pioneering technology firm at the forefront of innovative biotechnology solutions today announced an exciting strategic partnership with COEPTIS’ NexGenAI Affiliates Network and Arketyp Valu, a prominent devel...
COEPTIS NexGenAI Affiliates Network & MarketLeverage Announce Strategi...
COEPTIS NexGenAI Affiliates Network & MarketLeverage Announce Strategic Partnership to Revolutionize AI-Powered Affiliate Marketing This partnership gives COEPTIS access to AI-driven campaign management, predictive analytics, and automated outreach capabilities with MarketLeverage’s 5,500 advertisers and 55,000 publishers, creating one of the most expansive and effective affiliate networks in the industry WEXFORD, Pa., Feb. 20, 2025 (GLOBE NEWSWIRE) -- COEPTIS, Inc. (Nasdaq: COEP) ("the Company" or "Coeptis"), a pioneering technology firm at the forefront of innovative biotechnology sol...
COEPTIS NexGenAI Affiliates Network & MarketLeverage Announce Strategi...
COEPTIS NexGenAI Affiliates Network & MarketLeverage Announce Strategic Partnership to Revolutionize AI-Powered Affiliate Marketing This partnership gives COEPTIS access to AI-driven campaign management, predictive analytics, and automated outreach capabilities with MarketLeverage’s 5,500 advertisers and 55,000 publishers, creating one of the most expansive and effective affiliate networks in the industry WEXFORD, Pa., Feb. 19, 2025 (GLOBE NEWSWIRE) -- COEPTIS, Inc. (Nasdaq: COEP) ("the Company" or "Coeptis"), a pioneering technology firm at the forefront of innovative biotechnology so...
COEPTIS Announces the Launch of COEP Venture Group to Invest in AI, RP...
COEPTIS Announces the Launch of COEP Venture Group to Invest in AI, RPA, and AI Agent Startups WEXFORD, Pa., Feb. 13, 2025 (GLOBE NEWSWIRE) -- COEPTIS, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a pioneering technology company dedicated to advancing cutting-edge technologies and artificial intelligence at the forefront of innovative biotechnology therapeutic solutions, today announced the launch of COEP Venture Group, a newly established investment arm dedicated to funding and accelerating technology startups specializing in Artificial Intelligence (AI), Robotic Process Automation ...
- ACF Healthcare
Coeptistx (COEP) Deverra Deal Flash Note 21082023
Coeptis Therapeutics Inc. (NASDAQ: COEP), post Deverra deal is a Phase 1 clinical stage biotech (previously pre-clinical) in the oncology space. COEP’s exclusive license deal with Deverra for DVX201 (two products ’54’ & ‘16’ provides access to Deverra’s no-HLA-matching platform asset onto which COEP’s SNAP-CAR and GEAR platforms could dovetail’ and create a potentially very broad application set of immune technologies. Deverra’s proprietary allogeneic stem cell platform side steps patient donor ...
- ACF Healthcare
Coeptis Therapeutics Inc. (COEP) YE22 1Q23 & DeSPAC 29062023
Coeptis Therapeutics Inc. (NASDAQ: COEP) is a pre-clinical stage biopharmaceutical Corp focused on fighting cancer via a pipeline of potentially novel products targeting CD38+ related unmet need and solid tumor cancers. The YE22A results show wash through of the SPAC merger and redemptions, which may run around ~90%. The 1Q23A results add additional insights into operational costs in particular. During YE22A raise ‘costs’ are dominated by warrant liabilities and redemptions. The diagnostics plat...
- ACF Mining
Coeptis Therapeutics Inc. (COEP) Initiation Note ACF Equity Research 1...
Coeptis Therapeutics Inc. (NASDAQ: COEP) is a pre-clinical stage biopharmaceutical Corp focused on fighting cancer via a pipeline of potentially novel products targeting CD38+ related unmet need and solid tumor cancers. The up list to Nasdaq via the SPAC Bull Horn Holdings (BHSE) is a key milestone leaving COEP with 19,516,839 shares in issue, better liquidity and greater access to capital needed to advance its pipeline. We assess that there are multiple value drivers within COEP, including its ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.